Gyawali B - Search Results

1

Should the control arms of randomized trials have an expiry date?

Kartolo A, Gyawali B. Kartolo A, et al. Among authors: gyawali b. Nat Rev Clin Oncol. 2022 Jul;19(7):425-426. doi: 10.1038/s41571-022-00624-2. Nat Rev Clin Oncol. 2022. PMID: 35365795 No abstract available.

2

Drugs that lack single-agent activity: are they worth pursuing in combination?

Gyawali B, Prasad V. Gyawali B, et al. Nat Rev Clin Oncol. 2017 Apr;14(4):193-194. doi: 10.1038/nrclinonc.2017.27. Epub 2017 Mar 7. Nat Rev Clin Oncol. 2017. PMID: 28266519 No abstract available.

3

Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials.

Gyawali B, D'Andrea E, Franklin JM, Kesselheim AS. Gyawali B, et al. J Natl Compr Canc Netw. 2020 Jan;18(1):36-43. doi: 10.6004/jnccn.2019.7345. J Natl Compr Canc Netw. 2020. PMID: 31910385

4

Real-world evidence and regulatory drug approval.

Raphael MJ, Gyawali B, Booth CM. Raphael MJ, et al. Among authors: gyawali b. Nat Rev Clin Oncol. 2020 May;17(5):271-272. doi: 10.1038/s41571-020-0345-7. Nat Rev Clin Oncol. 2020. PMID: 32112057 No abstract available.

5

COVID-19 and cancer: do we really know what we think we know?

Robinson AG, Gyawali B, Evans G. Robinson AG, et al. Among authors: gyawali b. Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. doi: 10.1038/s41571-020-0394-y. Nat Rev Clin Oncol. 2020. PMID: 32424196 Free PMC article.

6

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Gyawali B, West HJ. Gyawali B, et al. J Clin Oncol. 2021 Jan 20;39(3):175-177. doi: 10.1200/JCO.20.01762. Epub 2020 Dec 4. J Clin Oncol. 2021. PMID: 33275490 No abstract available.

7

An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries.

Wells JC, Sharma S, Del Paggio JC, Hopman WM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Wells JC, et al. Among authors: gyawali b. JAMA Oncol. 2021 Mar 1;7(3):379-385. doi: 10.1001/jamaoncol.2020.7478. JAMA Oncol. 2021. PMID: 33507236 Free PMC article.

8

FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.

Gyawali B, Kesselheim AS. Gyawali B, et al. Nat Rev Clin Oncol. 2021 Jul;18(7):397-398. doi: 10.1038/s41571-021-00504-1. Nat Rev Clin Oncol. 2021. PMID: 33767454 No abstract available.

9

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.

Sharma S, Wells JC, Hopman WM, Del Paggio JC, Gyawali B, Hammad N, Hay AE, Booth CM. Sharma S, et al. Among authors: gyawali b. Curr Oncol. 2021 Apr 13;28(2):1518-1527. doi: 10.3390/curroncol28020143. Curr Oncol. 2021. PMID: 33924380 Free PMC article.

10

Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.

Fundytus A, Wells JC, Sharma S, Hopman WM, Del Paggio JC, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM. Fundytus A, et al. Among authors: gyawali b. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):28-35. doi: 10.1016/j.clon.2021.08.003. Epub 2021 Aug 31. Clin Oncol (R Coll Radiol). 2022. PMID: 34479769 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

306 results

Search Page